WHO Approves Mpox Vaccine, Aims to Curb Africa’s Outbreak
In cases of limited vaccine supply, WHO recommends single-dose distribution, which is 76% effective.
NEW YORK—The World Health Organization (WHO) has approved an Mpox vaccine for the first time, writes Winston Mwale.
This move is expected to facilitate “timely and increased access” for millions at risk in Africa, where over 20,000 cases have been reported this year.
The MVA-BN vaccine, developed by Danish pharmaceutical company Bavarian Nordic, received WHO prequalification on Friday.
It has already been approved in Europe and the United States for adult use. WHO’s approval aims to accelerate vaccine access, reduce transmission, and help contain the outbreak.
WHO Director-General Tedros Adhanom Ghebreyesus said, “The prequalification of this vaccine is an important step in the fight against the mpox virus in Africa and for the future.”
He emphasized the need for urgent scale-up in procurement, donations, and rollout.
“We must ensure equitable access to vaccines where they are needed most,” he added.
The MVA-BN vaccine is administered in two doses, four weeks apart, to individuals 18 years and older. It has an estimated effectiveness of 82%.
For infants, young children, pregnant women, and immunocompromised individuals, the vaccine may be used when the benefits outweigh the potential risks.
In cases of limited vaccine supply, WHO recommends single-dose distribution, which is 76% effective.
WHO stated that prequalification will aid in accelerating procurement by governments and international agencies like Gavi and UNICEF. It will also help fast-track regulatory approval by countries worldwide.